MedPath

Geron Corporation Advances in Myeloid Hematologic Malignancies Treatment

Geron Corporation, a biopharmaceutical company, is making strides in the treatment of myeloid hematologic malignancies with its drug imetelstat, currently in Phase 3 clinical trials.

Geron Corporation, established in 1990 and based in Foster City, California, is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of therapeutics for myeloid hematologic malignancies. The company is currently focusing on imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials. This innovative drug aims to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies, offering hope for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The progress of imetelstat through clinical trials represents a significant step forward in the battle against these challenging conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Geron Stock Rallies More Than 60% in a Year: Here's Why

Geron Corporation's stock surged over 60% in the past year, driven by the FDA approval and successful commercial launch of Rytelo for treating myelodysplastic syndromes, alongside strong financial backing and promising clinical trial results.

CHMP Recommends Approval of Geron's Rytelo for Lower-Risk Myelodysplastic Syndromes

The Committee for Medicinal Products for Human Use (CHMP) has recommended Rytelo (imetelstat) for approval in the EU for transfusion-dependent anemia due to lower-risk myelodysplastic syndromes.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.

Regen BioPharma Expands HemaXellerate Trial Scope Beyond Aplastic Anemia

Regen BioPharma's HemaXellerate, a stem cell-derived therapy, has received FDA clearance for a Phase 1 clinical trial initially focused on aplastic anemia.

Regen BioPharma's HemaXellerate™ Phase 1 Trial Aims to Redefine Aplastic Anemia Treatment

Regen BioPharma is advancing HemaXellerate™, a stem cell-derived therapy, into a Phase 1 clinical trial following FDA clearance, initially targeting aplastic anemia.

Geron's Rytelo Sees Strong Launch, H.C. Wainwright Assigns 'Buy' Rating

Geron's Rytelo (imetelstat) received FDA approval on June 6, 2024, for transfusion-dependent anemia in certain myelodysplastic syndromes.

FDA Approves RYTELO™ (imetelstat) for Transfusion-Dependent Anemia in Low-Risk MDS

The FDA has approved RYTELO™ (imetelstat) for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

FDA Approves Geron's RYTELO™ (imetelstat) for Lower-Risk MDS

The FDA has approved Geron's RYTELO™ (imetelstat) for adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia and are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA).

FDA Approves RYTELO™ (imetelstat) for Lower-Risk MDS with Transfusion-Dependent Anemia

The U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who suffer from transfusion-dependent anemia. This approval is based on the results from the IMerge Phase 3 clinical trial, which demonstrated significant benefits in terms of red blood cell transfusion independence and increases in hemoglobin levels among patients.

Geron's Imetelstat Shows Promise in MDS and Myelofibrosis Trials, NDA Submission on Track

Geron's Imetelstat demonstrated statistically significant improvements in transfusion independence in lower-risk MDS patients in the IMerge Phase 3 trial.

Reference News

[1]
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo Finance
finance.yahoo.com · Jan 7, 2025

Geron Corporation, established in 1990 and based in Foster City, CA, specializes in developing therapeutics for myeloid ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy